| US 7,517,531 B2 | ||
| Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4 | ||
| Stephen S. Whitehead, Montgomery Village, Md. (US); Brian R. Murphy, Bethesda, Md. (US); Lewis Markoff, Bethesda, Md. (US); Barry Falgout, Rockville, Md. (US); Joseph Blaney, Frederick, Md. (US); and Kathryn Hanley, Las Cruces, N. Mex. (US) | ||
| Assigned to The United States of America as represented by the Department of Health and Human Services, Washington, D.C. (US) | ||
| Filed on Oct. 21, 2004, as Appl. No. 10/970,640. | ||
| Application 10/970640 is a continuation of application No. PCT/US03/13279, filed on Apr. 25, 2003. | ||
| Claims priority of provisional application 60/377860, filed on May 03, 2002. | ||
| Claims priority of provisional application 60/436500, filed on Dec. 23, 2002. | ||
| Prior Publication US 2007/0009552 A1, Jan. 11, 2007 | ||
| Int. Cl. A61K 39/295 (2006.01); C12N 7/04 (2006.01) | ||
| U.S. Cl. 424—202.1 [424/218.1; 424/199.1; 424/205.1; 435/235.1; 435/320.1; 435/236] | 42 Claims |
| 1. A tetravalent immunogenic composition comprising
a) a first attenuated virus that is immunogenic against dengue serotype 1,
b) a second attenuated virus that is immunogenic against dengue serotype 2,
c) a third attenuated virus that is immunogenic against dengue serotype 3, and
d) a fourth attenuated virus that is immunogenic against dengue serotype 4,
wherein each of a), b), c) and d) comprises a nucleic acid comprising
i) a first nucleotide sequence encoding at least one structural protein from a first dengue virus,
ii) a second nucleotide sequence encoding nonstructural proteins from the first dengue virus or a second dengue virus, and
iii) a 3′ untranslated region, wherein the 3′ untranslated region contains a deletion of about 30 nucleotides corresponding
to the TL2 stem-loop structure, and wherein both the 3′ untranslated region and the second nucleotide sequence encoding nonstructural
proteins are from either the first dengue virus or the second dengue virus;
wherein the tetravalent immunogenic composition is not rDEN1/4Δ30, rDEN2/4Δ30, rDEN3/4Δ30, rDEN4Δ30.
|